Genomic Analysis And 3-Y Efficacy And Safety Update Of Combi-D: A Phase 3 Study Of Dabrafenib (D) Plus Trametinib (T) Vs D Monotherapy In Patients (Pts) With Unresectable Or Metastatic Braf V600e/K-Mutant Cutaneous Melanoma.
JOURNAL OF CLINICAL ONCOLOGY（2016）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要